Browsing by Author "Özcan, Ö"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A new weight-bearing meniscal test and a comparison with McMurray's test and joint line tenderness
    Akseki, D; Özcan, Ö; Boya, H; Pinar, H
    Purpose: The purpose of this study was to describe a new weight-bearing McMurray's test (Ege's test) and to compare its diagnostic value with McMurray's test and joint line tenderness (JLT). We also aimed to determine if associated lesions had any effect on the diagnostic values of the 3 tests. Type of Study: Prospective controlled trial, clinical study. Methods: The study group consisted of 150 consecutive patients who had had symptoms related to intra-articular knee pathology, and arthroscopic diagnoses were used as the gold standard. Results: There were a total of 211 diagnoses on arthroscopy. A meniscus tear was found in 127 of the 150 patients; 90 had medial, 28 had lateral, and 9 had tears of both menisci. There were no statistically significant differences between the 3 tests in detecting a meniscal tear (P > .05). However, better accuracy, sensitivity, and specificity rates were obtained with Ege's test for medial meniscal lesions (71%, 67%, and 81%, respectively). JLT also gave superior accuracy rates (71%), but the specificity of Ege's test was apparently higher than JLT (81% v 44%). The highest positive predictive value was also obtained with Ege's test (86%), whereas a superior negative predictive value was obtained with JLT (67%) in medial meniscal tears. Lateral meniscal tears were diagnosed more accurately than medial meniscal tears, and Ege's test gave results superior to the others (84%, 64%, 90% for accuracy, sensitivity, and specificity, respectively). Higher positive predictive values were obtained with McMurray's and Ege's tests than with JLT, but similar negative predictive values were achieved in all. A torn anterior cruciate ligament did not decrease the diagnostic values of the 3 tests, whereas the number of associated lesions in the knee negatively affected the diagnostic capabilities of the tests. Conclusions: Accuracies of traditional clinical meniscus tests may be improved by including Ege's test in the clinical examination. Level of Evidence: Level II, diagnostic.
  • No Thumbnail Available
    Item
    Effect of Impairment on the Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder in a National Survey: Nation-Wide Prevalence and Comorbidities of ADHD
    Ercan, ES; Unsel-Bolat, G; Tufan, AE; Demirkaya, SK; Bilac, O; Celik, G; Kiliç, BG; Ardic, UA; Sapmaz, SY; Aksu, H; Tahiroglu, AY; Karacetin, G; Tural, U; Aktepe, E; Arman, AR; Basgül, S; Coskun, M; Dursun, OB; Durukan, I; Fis, NP; Gençoglan, S; Gökçen, C; Gokten, ES; Görker, I; Görmez, V; Gündogdu, ÖY; Hesapçioglu, ST; Kandemir, H; Mutluer, T; Nasiroglu, S; Özcan, Ö; Sahin, N; Toros, F; Yazici, IP; Yazici, KU; Yulaf, Y; Yüksel, T; Bilgic, A; Altun, H; Akdemir, D; Mazlum, B; Memik, NÇ; Özdemir, DF; Üneri, Ö; Ünal, F
    Objective: This study aimed to determine the prevalence and comorbidities of attention-deficit hyperactivity disorder (ADHD) by evaluating a large-scale nation-wide sample of children. Method: The inclusion criterion was being enrolled as a 2nd, 3rd, or 4th-grade student. A semi-structured diagnostic interview (K-SADS-PL), DSM-IV-Based Screening Scale for Disruptive Behavior Disorders, and assessment of impairment (by both parents and teachers) were applied to 5,842 participants. Results: The prevalence of ADHD was 19.5% without impairment and 12.4% with impairment. Both ADHD with and without impairment groups had similar psychiatric comorbidity rates except for oppositional defiant disorder (ODD) and conduct disorder (CD) diagnoses. Impairment in the ADHD group resulted in significantly higher ODD and CD diagnoses. Conclusion: Even when impairment is not described, other psychiatric disorders accompany the diagnosis of ADHD and may cause impairment in the future. Impairment in the diagnosis of ADHD significantly increases the likelihood of ODD and CD.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
    Tombak, A; Tanrikulu, FP; Durusoy, SS; Dinçyürek, HD; Kaya, E; Ümit, EG; Yavasoglu, I; Mehtap, Ö; Deveci, B; Özcan, MA; Terzi, H; Okay, M; Sayinalp, N; Yilmaz, M; Okan, V; Kizikli, A; Özcan, Ö; Çetin, G; Demircioglu, S; Aydogdu, I; Saydam, G; Davulcu, EA; Ilhan, G; Uçar, MA; Özet, G; Akpinar, S; Turgut, B; Berber, I; Kurtoglu, E; Sönmez, M; Batur, DS; Yildirim, R; Özkocamaz, V; Günes, AK; Sahip, B; Ertop, S; Akay, OM; Bastürk, A; Dogu, MH; Akdeniz, A; Ünal, A; Seyhanli, A; Gürkan, E; Çekdemir, D; Ferhanoglu, B
    Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard deviation: 64.6 +/- 10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.